The logical choice of inhalation device in patients with bronchial asthma and chronic obstructive pulmonary disease


DOI: https://dx.doi.org/10.18565/therapy.2020.5.125-131

Malyavin A.G.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
The article contains the analysis of factors influencing the efficacy of inhalation therapy in patients with asthma and chronic obstructive pulmonary disease (COPD). The refuse from short-acting bronchodilatators for stopping asthma attacks and the inclusion of a fixed combination of budesonide + formoterol at all stages of therapy for this disease are validated. Data on the advantages of using the recently appeared Rapihaler delivery system and indications for the use of a combination of an inhaled corticosteroid and a long-acting β2-adrenergic agonist in COPD patients are also presented in the article.
Keywords: bronchial asthma, chronic obstructive pulmonary disease, choice of inhaler, Symbicort Rapihaler
Read entire article

Literature


  1. Rootmensen G.N., van Keimpema A.R.J., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010; 23(5): 323–28. doi: 10.1089/jamp.2009.0785.

  2. Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014; 24: 14009. doi: 10.1038/npjpcrm.2014.9.

  3. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. Royal College of Physicians. London; 2014.

  4. Schatz M., Zeiger R.S., Vollmeet W.M. et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol. 2006; 117(5): 995–1000. doi: 10.1016/j.jaci.2006.01.053.

  5. Partridge M.R., van der Molen T., Myrseth S.-E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006; 6: 13. doi: 10.1186/1471-2466-6-13.

  6. Stanford R.H., Shah M.B., D’Souza A.O. et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012; 109(6): 403–07. doi: 10.1016/j.anai.2012.08.014.

  7. Suissa S., Ernst P., Boivin J.F. et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994; 149(3 Pt 1): 604–10. doi: 10.1164/ajrccm.149.3.8118625.

  8. Dusser D., Montani D., Chanez P. et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007; 62(6): 591–604. doi: 10.1111/j.1398-9995.2007.01394.x.

  9. Reddel H.K., Ampon R.D., Sawyer S.M., Peters M.J. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017; 7(9): e016688. doi: 10.1136/bmjopen-2017-016688.

  10. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173(8): 842–46. doi: 10.1164/rccm.200508-1338PP.

  11. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2020. Available at: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (date of access – 01.08.2020).

  12. Бронхиальная астма. Федеральные клинические рекомендации. Российское респираторное общество (РРО). 2019 г. Доступ: http://spulmo.ru/upload/kr_bronhastma_2019.pdf (дата обращения – 01.08.2020). [Bronchial asthma. Federal guidelines. Russian Respiratory Society (RRO). 2019. Available at: http://spulmo.ru/upload/kr_bronhastma_2019.pdf (date of access – 01.08.2020)

  13. Horne R., Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999; 47(6): 555–67. doi: 10.1016/s0022-3999(99)00057-4.

  14. Терехова Е.П. Современные ингаляционные устройства, применяемые в лечении бронхиальной астмы. Эффективная фармакотерапия. 2013; 39: 24–39. [Terekhova Ye.P. Modern inhaler devices for asthma patients. Effektivnaya farmakoterapiya. 2013; 39: 24–39 (In Russ.)].

  15. Авдеев С.Н. Основы ингаляционной терапии. Дозированные аэрозольные ингаляторы. Астма и аллергия. 2013; 4: 2–7. [Avdeev S.N. Basics of inhalation therapy. Dosed aerosol inhalers. Astma i allergiya. 2013; 4: 2–7 (In Russ.)].

  16. Lavorini F., Corrigan C.J., Barnes P.J. et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011; 105(7): 1099–103. doi: 10.1016/j.rmed.2011.03.012.

  17. Haughney J., Price D., Barnes N.C. et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010; 104(9): 1237–45. doi: 10.1016/j.rmed.2010.04.012.

  18. Sander N., Fusco-Walkert S.J., Harder J.M., Chipps B.E. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann Allergy Asthma Immunol. 2006; 97(1): 34–38. doi: 10.1016/s1081-1206(10)61366-x.

  19. Chambers F., Ludzik A. In vitro drug delivery performance of a new budesonide/formoterol pressurized metered-dose inhaler. J Aerosol Med Pulm Drug Deliv. 2009; 22(2): 113–20. doi: 10.1089/jamp.2008.0697.

  20. Noonan M., Rosenwasser L.J., Martin P. et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma. Drugs. 2006; 66(17): 2235–54. doi: 10.2165/00003495-200666170-00006.

  21. Tunceli O., Williams S.A., Kernet D.M. et al. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis. J Allergy Clin Immunol Pract. 2014; 2(6): 719–26. doi: 10.1016/j.jaip.2014.07.016.

  22. World Health Organization. The top 10 causes of death. URL: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (date of access – 21.07.2020).

  23. Global initiative for obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Available at: https:// goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf (date of access – 01.08.2020).

  24. Клинические рекомендации. Хроническая обструктивная болезнь легких. Российское респираторное общество. 2018. Доступ: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf (дата обращения – 01.08.2020). [Clinical guidelines. Chronic obstructive pulmonary disease. Russian Respiratory Society. 2018. Available at: http://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf (date of access – 01.08.2020) (In Russ.)].

  25. Sharafkhaneh A., Southard J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012; 106(2): 257–68. doi: 10.1016/j.rmed.2011.07.020..


About the Autors

Andrey G. Malyavin, MD, professor, professor of the Department of phthisiology and pulmonology of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia, RSMSIM general secretary, chief freelance pulmonologist of Central Federal District of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/2 Losinoostrovskaya Str. E-mail: maliavin@mail.ru

Back to Content

Бионика Медиа